Skip to Main Content

Paper Details

Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Am J Nephrol
11
2022
AP, C3, C3 glomerulopathy, C3G, Danicopan, FD, Factor D, IC-, IC-MPGN, MPGN, Patients, danicopan, factor D, immune complex-mediated membranoproliferative glomerulonephritis, nephropathy, patients, proteinuria
Author NameAffiliation
Samir M ParikhThe Ohio State University Medical Center
Samir M ParikhThe Ohio State University Medical Center
James A Tumlin
  • 1 - 3

Datasets

Release 1.2